Mario Alberto Accardi, Ph.D.
Mario Alberto is CEO at Orthonika since co-founding the company in 2015. He is also Partner at London based life sciences venture capital fund Vita. He was previously with London based venture capital fund Fort Rock Capital, where he led investments and has been an active board member in a number of therapeutics, medical devices and digital health companies such as vasopharm GmbH, GNS Healthcare and various early stage seed projects. Prior to that he was with Entrepreneurs Fund, a pan-European venture fund with more than $200m of assets under management, where he supported multiple transactions including Prosonix’s sale to Circassia and Optinose (IPO on Nasdaq). Previously, Mario co-founded Sierra MedTech and was a consultant in the life sciences field with Deallus Consulting. Mario holds a Postgraduate in Genomic Medicine, a PhD in Biomedical Engineering and a First Class MEng degree in Mechanical Engineering all from Imperial College London. Mario’s academic research focused on early diagnosis of osteoarthritis, regenerative medicine techniques and orthopaedic biomechanics. He is an inventor in several granted and filed patents and has published in international peer reviewed scientific journals.
Dominique Kleyn, MBA
Dominique is COO at Orthonika since co-founding the company in 2015. She has wide experience of product, business and company development, starting as a Research Scientist for Unilever in the team that launched Clear Blue diagnostics through its Unipath subsidiary. She was Business Development Manager for GSK’s Wellcome Diagnostics subsidiary, licensing-in new product lines and transitioning the business through acquisition by Murex and subsequent 10x sale to Abbott. In 1999 she joined Imperial Innovations to build a portfolio of spin-outs such as Acrobot (sold to Stryker) and Protexeon (sold to Air Products) and became Head of Life Sciences Technology Transfer in anticipation of the company’s IPO in 2006. In 2009 she left Imperial to become CEO at London Genetics, raising £2m to deliver pharmacogenetic services in clinical development, and has since worked in various biotech executive and non-executive roles, including 2 years on the board of the BioIndustry Association and 5 years as a Trustee of the Genetics Society. She holds a BSc in Life Sciences and an MBA with a focus on Technology Entrepreneurship from Imperial College London. She is an LESi Certified Licensing Professional.
Professor Andrew Amis, FREng
Professor Amis is the Chair of Orthopaedic Biomechanics at Imperial College London as well as the Head of the Medical Engineering. He has 40 years of research in orthopaedic biomechanics, including the design of artificial human joints, tendons and ligaments and the mechanical analyses of biological systems and structures. He has over 300 peer-reviewed journal publications. In addition to research work, Andrew has acted as a consultant and expert witness for a number of areas of work, including implant design, failures of orthopaedic implants and industrial injuries.
Professor Justin Cobb, BM BCh MCh FRCS
Professor Cobb is the Chair in Orthopaedics at Imperial College London and is also the Founder of Acrobot, the worlds first haptic based robotic assistant. He is a Civilian advisor in orthopaedics to the Royal Air Force and is on the staff of King Edward VII hospital for Officers as well as being the Orthopaedic Surgeon to Her Majesty the Queen. Justin is a Graduate of Medicine at Magdalen College,Oxford. Justin’s research group is known to have secured £80m for the development of The Michael Uren Biomedical Engineering Hub which will enable engineers and medics to come together and develop new technologies.
Surbhi Gupta, Ph.D.
Surbhi joined Imperial Innovations in September 2015 and is responsible for commercializing opportunities arising from the Medtech area. Surbhi works predominantly with the Institute of Biomedical Engineering at Imperial College London. Prior to joining Imperial Innovations, Surbhi worked at King's College London and Cancer Research Technology (CRT) in similar roles leading on key revenue generating deals as well as spin-out company formation. Surbhi obtained her PhD in Biophysics from the Indian Institute of Science and followed this with post-doctoral research at the London Research Institute (LRI) where her work focused on understanding signalling pathways in tumour genesis.
Max Graziosi has worked for over 20 years in Capital Markets in a number of financial institutions in London including Credit Suisse, Bear Sterns and Nomura. He recently left Bank of America Merrill Lynch where he was a Managing Director, EMEA Chief Operating Officer for Fixed Income Currencies and Commodities. He has a vast experience in investing across many asset classes and industry sectors. He is an angel investor in a number of projects including The Kinase Project with Imperial Innovations Group plc, advancing LMTK3 as a therapeutic target for breast cancer and Maternal Matters Plc, a service providing social care to single mothers and their infants.